No decline in functional status or cognitive function during the first year after treatment initiation for early-stage breast cancer in women aged 75 years and older: a prospective observational matched cohort study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
This study compared functional and cognitive trajectories in older women treated for early breast cancer with matched women without cancer.
Methods
Data were derived from two Dutch cohorts: the CLIMB study (women aged ≥75 years with operable breast cancer) and the ISCOPE study (community-dwelling women aged ≥75 years without cancer). Breast cancer patients were matched 1:2 to controls on age and baseline functional or cognitive status. Functional status was assessed using the Groningen Activity Restriction Scale (GARS), and cognitive function using the Mini-Mental State Examination (MMSE). Longitudinal changes over 12 months were analyzed using both unadjusted and confounder-adjusted linear mixed models.
Results
168 breast cancer patients and 336 matched breast cancer-free controls were included with a mean age of 80 years. Most breast cancer patients had stage 0-I or II disease and received surgery and/or radiotherapy; 48% received adjuvant endocrine therapy, chemotherapy was rare (<1%). At baseline, both cohorts were comparable in age and functional or cognitive status, although there was a higher comorbidity burden in the control cohort. No significant differences in functional or cognitive decline were observed between the cohorts over 12 months.
Conclusions
In older women, early breast cancer and its treatment did not lead to accelerated decline in functional status or cognitive function within the first year compared to matched older women without cancer. These findings suggest that, for relatively fit older patients, breast cancer treatment may not accelerate functional decline in the short term.
